Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNE1 | P15382 | 1/20 | 0.53 |
| ▸ | KCNQ1 | P51787 | 1/20 | 0.53 |
| ▸ | ABCC9 | O60706 | 16/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13825287 | 0.83 | KCNE1 (0.56) | KCNE1KCNQ1ABCC9 | |
| SCHEMBL10638859 | 0.79 | KCNE1 (0.52) | KCNE1KCNQ1ABCC9 | |
| SCHEMBL10638845 | 0.79 | KCNE1 (0.52) | KCNE1KCNQ1ABCC9 | |
| SCHEMBL9032537 | 0.79 | KCNE1 (0.56) | KCNE1KCNQ1ABCC9 | |
| SCHEMBL9032549 | 0.79 | KCNE1 (0.56) | KCNE1KCNQ1ABCC9 | |
| SCHEMBL10638850 | 0.79 | KCNE1 (0.52) | KCNE1KCNQ1ABCC9 | |
| SCHEMBL9032544 | 0.79 | KCNE1 (0.56) | KCNE1KCNQ1ABCC9 | |
| SCHEMBL9221034 | 0.78 | KCNE1 (0.51) | KCNE1KCNQ1ABCC9 | |
| SCHEMBL9221043 | 0.78 | KCNE1 (0.51) | KCNE1KCNQ1ABCC9 | |
| SCHEMBL9221029 | 0.78 | KCNE1 (0.51) | KCNE1KCNQ1ABCC9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2582674-B1 | GPR120 RECEPTOR AGONISTS AND USES THEREOF | CYMABAY THERAPEUTICS INC (US) | 2014-10-01 | — | — | EP | disclosed |
| US-20140121246-A1 | GPR120 RECEPTOR AGONISTS AND USES THEREOF | METABOLEX, INC. (US) | 2014-05-01 | — | — | US | disclosed |
| US-8598374-B2 | GPR120 receptor agonists and uses thereof | METABOLEX, INC. (US) | 2013-12-03 | — | — | US | disclosed |
| US-8476308-B2 | GPR120 receptor agonists and uses thereof | METABOLEX, INC. (US) | 2013-07-02 | — | — | US | disclosed |
| US-8476308-B2 | GPR120 receptor agonists and uses thereof | METABOLEX, INC. (US) | 2013-07-02 | — | — | US | disclosed |
| US-20130131351-A1 | GPR120 RECEPTOR AGONISTS AND USES THEREOF | METABOLEX, INC. (US) | 2013-05-23 | — | — | US | disclosed |
| US-20130131351-A1 | GPR120 RECEPTOR AGONISTS AND USES THEREOF | METABOLEX, INC. (US) | 2013-05-23 | — | — | US | disclosed |
| US-20130109734-A1 | GPR120 RECEPTOR AGONISTS AND USES THEREOF | METABOLEX, INC. (US) | 2013-05-02 | — | — | US | disclosed |
| US-20130109734-A1 | GPR120 RECEPTOR AGONISTS AND USES THEREOF | METABOLEX, INC. (US) | 2013-05-02 | — | — | US | disclosed |
| EP-2582674-A1 | GPR120 RECEPTOR AGONISTS AND USES THEREOF | Metabolex Inc. (US) | 2013-04-24 | — | — | EP | disclosed |
| US-8309600-B2 | GPR120 receptor agonists and uses thereof | METABOLEX INC. (US) | 2012-11-13 | — | — | US | disclosed |
| US-8299117-B2 | GPR120 receptor agonists and uses thereof | METABOLEX INC. (US) | 2012-10-30 | — | — | US | disclosed |
| US-8299117-B2 | GPR120 receptor agonists and uses thereof | METABOLEX INC. (US) | 2012-10-30 | — | — | US | disclosed |
| EP-2514745-A1 | GPR120 receptor agonists and uses thereof | Metabolex Inc. (US) | 2012-10-24 | — | — | EP | disclosed |
| US-20110313003-A1 | GPR120 RECEPTOR AGONISTS AND USES THEREOF | METABOLEX, INC. | 2011-12-22 | — | — | US | disclosed |
| US-20110313003-A1 | GPR120 RECEPTOR AGONISTS AND USES THEREOF | METABOLEX, INC. | 2011-12-22 | — | — | US | disclosed |
| WO-2011159297-A1 | GPR120 RECEPTOR AGONISTS AND USES THEREOF | METABOLEX, INC. (US) | 2011-12-22 | — | — | WO | disclosed |
| EP-2367793-A1 | GPR120 RECEPTOR AGONISTS AND USES THEREOF | Metabolex Inc. (US) | 2011-09-28 | — | — | EP | disclosed |
| US-20100190831-A1 | GPR120 RECEPTOR AGONISTS AND USES THEREOF | METABOLEX, INC. | 2010-07-29 | — | — | US | disclosed |
| WO-2010080537-A1 | GPR120 RECEPTOR AGONISTS AND USES THEREOF | METABOLEX, INC. (US) | 2010-07-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110313003-A1 | GPR120 RECEPTOR AGONISTS AND USES THEREOF | GPR119, GPR52, GCGR | KCNE1 2382/4885KCNQ1 1610/4885ABCC9 2653/4885 |
| US-20100190831-A1 | GPR120 RECEPTOR AGONISTS AND USES THEREOF | GPR119, GPR52, GCGR | KCNE1 2382/4885KCNQ1 1610/4885ABCC9 2653/4885 |
| US-20140121246-A1 | GPR120 RECEPTOR AGONISTS AND USES THEREOF | GPR119, GPR52, GCGR | KCNE1 2382/4885KCNQ1 1610/4885ABCC9 2653/4885 |
| US-20130109734-A1 | GPR120 RECEPTOR AGONISTS AND USES THEREOF | GPR119, GPR52, GCGR | KCNE1 2382/4885KCNQ1 1610/4885ABCC9 2653/4885 |
| US-20130131351-A1 | GPR120 RECEPTOR AGONISTS AND USES THEREOF | GPR119, GPR52, GCGR | KCNE1 2382/4885KCNQ1 1610/4885ABCC9 2653/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.